Literature DB >> 26641943

How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.

P J Klasse1.   

Abstract

Vaccines that protect against viral infections generally induce neutralizing antibodies. When vaccines are evaluated, the need arises to assess the affinity maturation of the antibody responses. Binding titers of polyclonal sera depend not only on the affinities of the constituent antibodies but also on their individual concentrations, which are difficult to ascertain. Therefore an assay based on chaotrope disruption of antibody-antigen complexes was designed for measuring binding strength. This assay works well with many viral antigens but gives differential results depending on the conformational dependence of epitopes on complex antigens such as the envelope glycoprotein of HIV-1. Kinetic binding assays might offer alternatives, since they can measure average off-rate constants for polyclonal antibodies in a serum. Here, potentials and fallacies of these techniques are discussed.

Entities:  

Keywords:  HIV Env; Vaccine; affinity; antibody; avidity; chaotrope; kinetic constants; neutralization; surface plasmon resonance; virus

Mesh:

Substances:

Year:  2016        PMID: 26641943      PMCID: PMC4766047          DOI: 10.1586/14760584.2016.1128831

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  124 in total

1.  Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space.

Authors:  K Andersson; L Choulier; M D Hämäläinen; M H van Regenmortel; D Altschuh; M Malmqvist
Journal:  J Mol Recognit       Date:  2001 Jan-Feb       Impact factor: 2.137

2.  A cluster of continuous antigenic structures in the transmembrane protein of HIV-1: individual patterns of reactivity in human sera.

Authors:  P J Klasse; R Pipkorn; J Blomberg
Journal:  Mol Immunol       Date:  1991-06       Impact factor: 4.407

3.  Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet.

Authors:  Yasmina Abdiche; Dan Malashock; Alanna Pinkerton; Jaume Pons
Journal:  Anal Biochem       Date:  2008-03-25       Impact factor: 3.365

4.  Problems and pitfalls with measurement of antibody affinity using solid phase binding in the ELISA.

Authors:  P A Underwood
Journal:  J Immunol Methods       Date:  1993-08-26       Impact factor: 2.303

5.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

6.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

Review 7.  Antiviral antibody responses: the two extremes of a wide spectrum.

Authors:  Lars Hangartner; Rolf M Zinkernagel; Hans Hengartner
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

Review 8.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

9.  Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.

Authors:  Yen T Duong; Maofeng Qiu; Anindya K De; Keisha Jackson; Trudy Dobbs; Andrea A Kim; John N Nkengasong; Bharat S Parekh
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  31 in total

1.  Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem.

Authors:  Elene Clemens; Davide Angeletti; Beth C Holbrook; Masaru Kanekiyo; Matthew J Jorgensen; Barney S Graham; Jonathan Yewdell; Martha A Alexander-Miller
Journal:  JCI Insight       Date:  2020-03-12

2.  HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Authors:  Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

3.  A facile method of mapping HIV-1 neutralizing epitopes using chemically masked cysteines and deep sequencing.

Authors:  Rohini Datta; Rohan Roy Chowdhury; Kavyashree Manjunath; Luke Elizabeth Hanna; Raghavan Varadarajan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-09       Impact factor: 11.205

4.  The interaction of anti-DNA antibodies with DNA antigen: Evidence for hysteresis for high avidity binding.

Authors:  David S Pisetsky; Robert Shaffer; Dustin D Armstrong; Diane M Spencer
Journal:  Clin Immunol       Date:  2021-09-04       Impact factor: 10.190

5.  Antibody-antigen kinetics constrain intracellular humoral immunity.

Authors:  Maria Bottermann; Heidrun Elisabeth Lode; Ruth E Watkinson; Stian Foss; Inger Sandlie; Jan Terje Andersen; Leo C James
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

Review 6.  Prospects from systems serology research.

Authors:  Kelly B Arnold; Amy W Chung
Journal:  Immunology       Date:  2017-12-01       Impact factor: 7.397

7.  Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties.

Authors:  Charlotte Givord; Iain Welsby; Sophie Detienne; Séverine Thomas; Assiya Assabban; Viviana Lima Silva; Céline Molle; Romain Gineste; Marjorie Vermeersch; David Perez-Morga; Oberdan Leo; Catherine Collignon; Arnaud M Didierlaurent; Stanislas Goriely
Journal:  NPJ Vaccines       Date:  2018-06-28       Impact factor: 7.344

8.  An R848-Conjugated Influenza Virus Vaccine Elicits Robust Immunoglobulin G to Hemagglutinin Stem in a Newborn Nonhuman Primate Model.

Authors:  Elene A Clemens; Beth C Holbrook; Masaru Kanekiyo; Jonathan W Yewdell; Barney S Graham; Martha A Alexander-Miller
Journal:  J Infect Dis       Date:  2021-07-15       Impact factor: 5.226

9.  Computational modeling of microfluidic data provides high-throughput affinity estimates for monoclonal antibodies.

Authors:  Sonia Budroni; Francesca Buricchi; Andrea Cavallone; Gianfranco Volpini; Alessandra Mariani; Paola Lo Surdo; Christoph J Blohmke; Giuseppe Del Giudice; Duccio Medini; Oretta Finco
Journal:  Comput Struct Biotechnol J       Date:  2021-06-17       Impact factor: 7.271

Review 10.  Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.

Authors:  Marc H V Van Regenmortel
Journal:  Int J Mol Sci       Date:  2016-09-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.